Phesgo subcutaneous
WebJun 23, 2024 · Phesgo Injection, Subcutaneous Solution Pertuzumab is a humanized monoclonal antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to interact with other HER family members (HER1, HER2, … WebOct 13, 2024 · Dosage for Phesgo The initial dose of Phesgo is 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase administered subcutaneously over approximately 8 minutes, followed every 3 weeks by a dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase administered subcutaneously over …
Phesgo subcutaneous
Did you know?
WebPhesgo is supplied as: 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15mL (80 mg, 40 mg, and 2,000 units/mL) of solution in a single-dose vial. 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase/10 mL (60 mg, 60 mg, and 2,000 units/mL) of solution in a single-dose vial. WebThe most common way of having trastuzumab and pertuzumab together is as a combination of the 2 drugs called Phesgo®. You have this as an injection under the skin (subcutaneous) every 3 weeks. This is a much quicker and easier way of …
WebJul 27, 2024 · Phesgo (chemical name: pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a fixed-dose combination of Herceptin (chemical name: trastuzumab), Perjeta (chemical name: pertuzumab), and hyaluronidase-zzxf to treat all stages of HER2-positive breast cancer in combination with chemotherapy. WebPhesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase [rHuPH20]) will be administered in the first cycle (1 cycle is 21 days).
WebPHESGO is a fixed-dose, subcutaneous combination of pertuzumab, trastuzumab and hyaluronidase in a single vial. The following video will review key points on how to properly store, prepare, and administer PHESGO. On screen: Image of vial used for illustrative purposes only. Let’s start with the product itself. WebOct 13, 2024 · PHESGO for subcutaneous injection contains pertuzumab, trastuzumab, and hyaluronidase [see DESCRIPTION]. Pertuzumab Pregnant cynomolgus monkeys were treated on Gestational Day ( GD ) 19 with loading doses of 30 to 150 mg/kg pertuzumab, followed by bi- weekly doses of 10 to 100 mg/kg.
WebPHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or …
WebNote: Phesgo injection for subcutaneous use has different dosage and administration instructions than intravenous pertuzumab and trastuzumab products. Phesgo is supplied as: 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15mL (80 mg, 40 mg, and 2,000 units/mL) of solution in a single-dose vial. ... cyber monday columbia coatscyber monday compact ice makerWebPHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection is a sterile, preservative-free, clear to opalescent, and colorless to slightly brownish solution supplied in single-dose vials for subcutaneous administration. PHESGO injection is supplied as two different configurations: cyber monday comicsWebJun 29, 2024 · Because it’s given as an injection, a healthcare professional can give you Phesgo in your home, avoiding a trip to a treatment center. When a medicine is injected under the skin, it’s called a subcutaneous injection. Phesgo can be used in combination with chemotherapy: before surgery to treat early-stage or inflammatory HER2-positive breast … cheap mini coffee tableWebNov 1, 2024 · Phesgo is for subcutaneous use only in the thigh. Do not administer intravenously. Phesgo has different dosage and administration instructions than intravenous pertuzumab, intravenous trastuzumab, and subcutaneous … cyber monday color laser printerWebOur ENHANZE technology is based on our patented recombinant human hyaluronidase PH20 enzyme, rHuPH20, which locally degrades hyaluronan (HA) in the subcutaneous (SC) space temporarily removing a barrier to fluid flow. This allows for large volume SC injection with increased dispersion and absorption of co-administered therapies. cyber monday comic booksWebJun 29, 2024 · Today, the U.S. Food and Drug Administration approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with... cyber monday color printers